% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ali:186245,
      author       = {E. Ali and A. Trailin and F. Ambrozkiewicz and V. Liška
                      and K. Hemminki$^*$},
      title        = {{A}ctivated {H}epatic {S}tellate {C}ells in
                      {H}epatocellular {C}arcinoma: {T}heir {R}ole as a
                      {P}otential {T}arget for {F}uture {T}herapies.},
      journal      = {International journal of molecular sciences},
      volume       = {23},
      number       = {23},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2022-03039},
      pages        = {15292},
      year         = {2022},
      note         = {#LA:C020#},
      abstract     = {Hepatocellular carcinoma (HCC) is a global healthcare
                      challenge, which affects more than 815,000 new cases every
                      year. Activated hepatic stellate cells (aHSCs) remain the
                      principal cells that drive HCC onset and growth. aHSCs
                      suppress the anti-tumor immune response through interaction
                      with different immune cells. They also increase the
                      deposition of the extracellular matrix proteins, challenging
                      the reversion of fibrosis and increasing HCC growth and
                      metastasis. Therapy for HCC was reported to activate HSCs,
                      which could explain the low efficacy of current treatments.
                      Conversely, recent studies aimed at the deactivation of HSCs
                      show that they have been able to inhibit HCC growth. In this
                      review article, we discuss the role of aHSCs in HCC
                      pathophysiology and therapy. Finally, we provide suggestions
                      for the experimental implementation of HSCs in HCC
                      therapies.},
      subtyp        = {Review Article},
      keywords     = {fibrosis regression (Other) / hepatic stellate cells
                      (Other) / hepatocellular carcinoma (Other) / therapeutic
                      studies (Other)},
      cin          = {C020},
      ddc          = {540},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36499616},
      doi          = {10.3390/ijms232315292},
      url          = {https://inrepo02.dkfz.de/record/186245},
}